HONG KONG – Australian researchers at the University of Adelaide's Robinson Research Institute (RRI) have successfully tested a drug showing early promise for preventing pre-term birth in mice, by suppressing inflammatory mechanisms underlying premature delivery. Read More

HONG KONG – Newly capitalized, thanks to an IPO of its contract drug manufacturing arm that surged on its first day of trading, South Korea's Samsung Group is now looking to take a larger slice of the global biotechnology market pie. Read More

HONG KONG – Biotech companies worldwide are gearing up to expand into the China market even as the CFDA toughens up its health care market through a series of reforms. Read More

SHANGHAI – Leaving politics aside, a Taiwanese company and a China counterpart plan to set up a $102 million joint venture to develop a dual drug, oral direct-acting antiviral treatment for chronic hepatitis C virus (HCV). Read More

Hutchison China Meditech Ltd., or Chi-Med, of Hong Kong, reported that data from a recent phase I dose escalation study of single and multiple doses of its spleen tyrosine kinase, HMPL-523, showed all doses to be generally safe and well tolerated. A multiple-dose regimen of 300 mg or less of HMPL-523, administered once daily, was recommended for future phase II trials of the candidate in autoimmune diseases. Read More